Search results for "cdkn2a"

showing 10 items of 22 documents

p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas.

2006

We assessed the frequency of genomic deletion of p16 INK4A (CDKN2A) in synovial sarcomas (SSs) and its possible association with immunoexpression of p16 and cyclin D1 and the Ki-67 proliferation index using dualcolor fluorescence in situ hybridization (FISH) on tissue microarray sections of 41 histologically and molecularly confirmed SSs. A heterozygous p16 INK4A gene deletion was identified in 28 (74%) of 38 cases, with 25 (89%) of them showing abnormal p16 protein expression (20 negative and 5 heterogeneous). Of 25 cases, 19 (76%) exhibiting increased cyclin D1 expression also demonstrated heterozygous p16 INK4A deletion. No significant association was observed between p16 INK4A deletion …

HeterozygoteProliferation indexTumor suppressor geneSoft Tissue NeoplasmsBiologySarcoma SynovialCyclin D1CDKN2ACyclin DCyclinsmedicineBiomarkers TumorHumansCDKN2A Gene DeletionCyclin-Dependent Kinase Inhibitor p16In Situ Hybridization FluorescenceCell Nucleusmedicine.diagnostic_testGeneral Medicinemedicine.diseaseImmunohistochemistrySynovial sarcomaKi-67 AntigenTumor progressionTissue Array AnalysisCancer researchGene DeletionFluorescence in situ hybridizationAmerican journal of clinical pathology
researchProduct

Identification of New Genetic Clusters in Glioblastoma Multiforme: EGFR Status and ADD3 Losses Influence Prognosis

2020

Glioblastoma multiforme (GB) is one of the most aggressive tumors. Despite continuous efforts to improve its clinical management, there is still no strategy to avoid a rapid and fatal outcome. EGFR amplification is the most characteristic alteration of these tumors. Although effective therapy against it has not yet been found in GB, it may be central to classifying patients. We investigated somatic-copy number alterations (SCNA) by multiplex ligation-dependent probe amplification in a series of 137 GB, together with the detection of EGFRvIII and FISH analysis for EGFR amplification. Publicly available data from 604 patients were used as a validation cohort. We found statistical associations…

IDHMaleOncologymedicine.medical_specialtyDNA Copy Number VariationsEGFRSCNAsurvivalArticleText miningCDKN2AInternal medicineHumansMedicineMultiplexlcsh:QH301-705.5<i>IDH</i>Brain Neoplasmsbusiness.industryGene AmplificationglioblastomaGeneral MedicineMiddle AgedADD3Prognosismedicine.diseaseSurvival AnalysisErbB ReceptorsMSH6high throughout techniqueslcsh:Biology (General)ADD3Multigene FamilyCalmodulin-Binding ProteinsFemaleprecisionIdentification (biology)businessSignal TransductionGlioblastomaCells
researchProduct

Ink4/Arf locus restores glucose tolerance and insulin sensitivity by reducing hepatic steatosis and inflammation in mice with impaired IRS2-dependent…

2015

Single nucleotide polymorphisms near the Ink4/Arf locus have been associated with type-2 diabetes mellitus. Previous studies indicate a protective role of the locus in the carbohydrate metabolism derangement associated with ageing in wild-type mice. The present study demonstrates that the increased Ink4/Arf locus expression in 1-year-old mice, partially-deficient for the insulin receptor substrate (IRS)2 (Irs2 +/-SuperInk4/Arf mice) ameliorates hepatic steatosis, inflammation and insulin resistance. Irs2 +/-SuperInk4/Arf mice displayed improved glucose tolerance and insulin sensitivity compared with Irs2 +/- mice which were glucose intolerant and insulin resistant compared with age-matched …

Inflammationmedicine.medical_specialtySteatosisMacrophageInsulinmedicine.medical_treatmentDiabetesInsulin resistanceCarbohydrate metabolismBiologymedicine.diseaseIRS2EndocrinologyInsulin resistanceInternal medicineInsulin receptor substratemedicineMolecular MedicineGlucose homeostasisSteatosisCDKN2A/2BMolecular BiologyProtein kinase BBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Absence of germline CDKN2A mutation in Sicilian Patients with Familial Malignant Melanoma: could it be a population-specific genetic signature?

2015

Germline CDKN2A mutations have been described in 25% to 40% of melanoma families from several countries. Sicilian population is genetically different from the people of Europe and Northern Italy because of its historical background, therefore familial melanoma could be due to genes different from high-penetrance CDKN2A gene. Four hundred patients with cutaneous melanoma were observed in a 6-years period at the Plastic Surgery Unit of the University of Palermo. Forty-eight patients have met the criteria of the Italian Society of Human Genetics (SIGU) for the diagnosis of familial melanoma and were screened for CDKN2A and CDK4 mutations. Mutation testing revealed that none of the families car…

Male0301 basic medicineCancer ResearchMutation rateSettore MED/06 - Oncologia MedicaSettore MED/19 - Chirurgia Plasticap14ARFGermline0302 clinical medicineCDKN2ATumor Suppressor Protein p14ARFMedicineMelanomaSicilyfamilial melanomaGeneticseducation.field_of_studyMelanomaMiddle AgedGene Expression Regulation NeoplasticItalyOncologygermline mutation030220 oncology & carcinogenesisMolecular MedicineFemaleResearch PaperSignal TransductionAdultPopulation03 medical and health sciencesCDKN2Acutaneous melanomaGermline mutationp16INK4aHumansGenetic Predisposition to DiseaseeducationneoplasmsCyclin-Dependent Kinase Inhibitor p16Germ-Line MutationAgedPharmacologybusiness.industryGenetic heterogeneityp.R87W mutationmedicine.disease030104 developmental biologyMutationCutaneous melanomaCDKN2A; cutaneous melanoma; familial melanoma; germline mutation; p.R87W mutation; p14ARF; p16INK4a; Cancer Research; Oncology; Molecular Medicine; Pharmacologybusiness
researchProduct

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment

2016

// Marta Jessica Llorca-Cardenosa 1, * , Tania Fleitas 1, * , Maider Ibarrola-Villava 1 , Maria Pena-Chilet 1 , Cristina Mongort 2 , Carolina Martinez-Ciarpaglini 2 , Lara Navarro 2 , Valentina Gambardella 1 , Josefa Castillo 1 , Susana Rosello 1 , Samuel Navarro 2 , Gloria Ribas 1 , Andres Cervantes 1 1 Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain 2 Department of Pathology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain * These authors contributed equally to this work Correspondence to: Gloria Ribas, email: gribas@incliva.es Andres Cervantes, email: andres.cervantes@uv.es Keywords: RUNX3, ARID1A, gastric ca…

Male0301 basic medicineRUNX3immune microenvironmentBiologyEpigenesis Genetic03 medical and health sciences0302 clinical medicineStomach NeoplasmsCDKN2ABiomarkers TumorTumor MicroenvironmentmedicineHumansEpigeneticsPromoter Regions GeneticAgedAged 80 and overTumor microenvironmentgastric cancerMicrosatellite instabilityCancerMethylationDNA MethylationMiddle AgedPrognosismedicine.diseaseARID1Adigestive system diseasesSurvival RateCore Binding Factor Alpha 3 Subunit030104 developmental biologyOncologyTumor progressionCase-Control Studies030220 oncology & carcinogenesisDNA methylationImmunologyCancer researchCpG IslandsFemaleMicrosatellite InstabilityFollow-Up StudiesResearch Papergene methylationOncotarget
researchProduct

The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.

2014

The Ewing sarcoma family of tumors (EFT) is a group of highly malignant small round blue cell tumors occurring in children and young adults. We report here the largest genomic survey to date of 101 EFT (65 tumors and 36 cell lines). Using a combination of whole genome sequencing and targeted sequencing approaches, we discover that EFT has a very low mutational burden (0.15 mutations/Mb) but frequent deleterious mutations in the cohesin complex subunit STAG2 (21.5% tumors, 44.4% cell lines), homozygous deletion of CDKN2A (13.8% and 50%) and mutations of TP53 (6.2% and 71.9%). We additionally note an increased prevalence of the BRCA2 K3326X polymorphism in EFT patient samples (7.3%) compared …

MaleCancer ResearchCell Cycle Proteinsmedicine.disease_causeFusion geneCDKN2AMedicine and Health Sciences2.1 Biological and endogenous factorsAetiologyChildGenetics (clinical)CancerPediatricMutationTissue microarrayTumorGenomeSarcomasHigh-Throughput Nucleotide SequencingAntigens NuclearSarcomaNeoplasm ProteinsOncologyChild PreschoolFemaleSarcomaResearch ArticleBiotechnologyHumanAdultPediatric Research Initiativelcsh:QH426-470Cohesin complexAdolescentPediatric CancerEwing SarcomaSarcoma EwingBiologyDisease-Free SurvivalFrameshift mutationCell LineGermline mutationRare DiseasesCell Line TumorEwingCancer GeneticsmedicineGeneticsHumansNuclearGenetic TestingAntigensPreschoolMolecular BiologyEcology Evolution Behavior and SystematicsGenome HumanHuman GenomeBiology and Life SciencesCancers and NeoplasmsInfantmedicine.diseaselcsh:GeneticsOrphan DrugMutationCancer researchGene DeletionDevelopmental Biology
researchProduct

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

2013

Background Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial mouse tumor, the CT26 colon carcinoma cell line. Results We found that Kras is homozygously mutated at p.G12D, Apc and Tp53 are not mutated, and Cdkn2a is homozygously deleted. Proliferation and stem-cell markers, including Top2a, Birc5 (Survivin), Cldn6 and Mki67, are highly expressed while differentiation and top-crypt markers Muc2, Ms4a8a (MS4A8B) and Epcam are not. Myc, Trp53 (tp53), Mdm2, Hif1a, and Nras are highly expressed while Egfr and Flt1 are not. MHC class I but not MHC class…

Neuroblastoma RAS viral oncogene homologmedicine.disease_causeMajor histocompatibility complexPolymorphism Single NucleotideProto-Oncogene Proteins p21(ras)TranscriptomeMiceAntigenAntigens NeoplasmCDKN2ACell Line TumorMHC class ImedicineGeneticsAnimalsCancer modelsComputational immunologyCyclin-Dependent Kinase Inhibitor p16Mice Inbred BALB CMHC class IIbiologyCarcinomaHigh-Throughput Nucleotide SequencingSequence Analysis DNAColorectal cancerMolecular biologyColonic Neoplasmsbiology.proteinImmunotherapyKRASTranscriptomeResearch ArticleBiotechnologyBMC Genomics
researchProduct

PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION

2019

Abstract BACKGROUND Children with pediatric low grade glioma’s (PLGG) harboring BRAF V600E mutation have poor outcome due to relative resistance to chemo-radiation and higher risk of malignant transformation. However, the role of targeted BRAF inhibition in these tumors is poorly defined. METHODS We assembled an international cohort of children with BRAF V600E mutant gliomas treated with BRAF inhibition, from 29 centers participating in the PLGG taskforce, and collected response, survival and molecular parameters. RESULTS Sixty-seven patients were treated with BRAFi (56 PLGG and 11 high grade gliomas) for a median time of 17.4 months (6 – 61 months), with 13 PLGG treated upfront. Objective …

OncologyCancer Researchmedicine.medical_specialtyChemotherapyPediatric Clinical Trialsbusiness.industrymedicine.medical_treatmentmedicine.diseaseChemotherapy regimenDiscontinuationOncologyCDKN2AConcomitantInternal medicineGliomamedicineNeurology (clinical)Progression-free survivalbusinessProspective cohort studyNeuro-Oncology
researchProduct

MELANOMA FAMILIARE. ANALISI DEI RISULTATI DELLO SCREENING DELLA MUTAZIONE DEL GENE CDKN2A NELLA POPOLAZIONE SICILIANA.

familial melanoma; hereditary melanoma; CDKN2A susceptibility genesCDKN2A susceptibility genesSettore MED/19 - Chirurgia Plasticahereditary melanomafamilial melanoma
researchProduct

Molecular Progression in Unusual Recurrent Non-Pediatric Intracranial Clear Cell Meningioma

2017

We report a case of a recurrent clear cell meningioma (CCM) in the frontal lobe of the brain of a 67-year-old man. The patient developed three recurrences: at 3, 10, and 12 years after his initial surgery. Histopathology observations revealed a grade 2 CCM with positivity for vimentin and epithelial membrane antigen. Expression of E-cadherin was positive only in the primary tumour and in the first available recurrence. Fluorescence in situ hybridization analyses demonstrated 1p and 14q deletions within the last recurrence. Multiplex ligation-dependent probe amplification studies revealed a heterozygous partial NF2 gene deletion, which progressed to total loss in the last recurrence. The las…

medicine.medical_specialtyPathologyrecurrenceCase ReportVimentin03 medical and health sciences0302 clinical medicineCDKN2ACDKN2BmedicineClear Cell MeningiomaNeoplasmgeneticstumour suppressor genesbiologymedicine.diagnostic_testbusiness.industryintracranial diseaseClear cell meningiomamedicine.diseaseFrontal lobemolecular progressionNF2030220 oncology & carcinogenesisbiology.proteinHistopathologynon-pediatric diseasebusiness030217 neurology & neurosurgeryFluorescence in situ hybridizationCurrent Oncology
researchProduct